ALX ONCOLOGY ($ALXO) posted quarterly earnings results on Tuesday, August 12th. The company reported earnings of -$0.49 per share, missing estimates of -$0.46 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $ALXO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALX ONCOLOGY Insider Trading Activity
ALX ONCOLOGY insiders have traded $ALXO stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $ALXO stock by insiders over the last 6 months:
- JASON LETTMANN (CHIEF EXECUTIVE OFFICER) sold 2,159 shares for an estimated $2,483
- SHELLY PINTO (SVP, FINANCE AND CAO) has made 0 purchases and 3 sales selling 4,093 shares for an estimated $2,196.
- JAUME PONS (PRESIDENT & CSO) sold 1,326 shares for an estimated $1,525
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALX ONCOLOGY Hedge Fund Activity
We have seen 25 institutional investors add shares of ALX ONCOLOGY stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY removed 2,140,642 shares (-85.7%) from their portfolio in Q1 2025, for an estimated $1,333,619
- FMR LLC removed 1,829,568 shares (-98.8%) from their portfolio in Q1 2025, for an estimated $1,139,820
- BLACKROCK, INC. removed 1,597,503 shares (-69.0%) from their portfolio in Q2 2025, for an estimated $663,123
- MILLENNIUM MANAGEMENT LLC removed 1,185,026 shares (-55.7%) from their portfolio in Q1 2025, for an estimated $738,271
- MPM BIOIMPACT LLC removed 841,434 shares (-60.5%) from their portfolio in Q1 2025, for an estimated $524,213
- GEODE CAPITAL MANAGEMENT, LLC removed 455,486 shares (-59.1%) from their portfolio in Q2 2025, for an estimated $189,072
- BANK OF AMERICA CORP /DE/ added 416,452 shares (+40.2%) to their portfolio in Q1 2025, for an estimated $259,449
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALX ONCOLOGY Analyst Ratings
Wall Street analysts have issued reports on $ALXO in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- UBS issued a "Buy" rating on 05/21/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/09/2025
- Piper Sandler issued a "Overweight" rating on 03/06/2025
- Jefferies issued a "Buy" rating on 03/06/2025
To track analyst ratings and price targets for ALX ONCOLOGY, check out Quiver Quantitative's $ALXO forecast page.
ALX ONCOLOGY Price Targets
Multiple analysts have issued price targets for $ALXO recently. We have seen 5 analysts offer price targets for $ALXO in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Colin Bristow from UBS set a target price of $1.0 on 05/21/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $2.0 on 05/09/2025
- Bradley Canino from Stifel set a target price of $1.5 on 03/07/2025
- Christopher Raymond from Piper Sandler set a target price of $9.0 on 03/06/2025
- Michael Yee from Jefferies set a target price of $3.0 on 03/06/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
